Meta-level question: how do you evaluate evidence for huperzine A when the human data is thin and most trials are small?
Loose evidence is not the same as no evidence and people overcorrect in both directions.
What surprised me is how much of the perceived benefit was routine and attention rather than pharmacology.
There is a serious question about whether the studied form matches what is sold, and nobody in a thread can answer it.
Two weeks is not enough time to attribute anything to a compound unless the effect is dramatic.
Would like a narrow answer rather than an enthusiastic one.
Read methods.
Narrow conclusion, briefly right. Broad conclusion, interestingly wrong. I know which I keep choosing. Same for me with huperzine A, unfortunately.
This is the kind of post the forum exists for.
Loose evidence is not nothing, but a washout either side is the only reason to trust your own take. How long have you been on huperzine A?
Baseline first. Not on huperzine A but the pattern is familiar.
Stupid question: how do you know whether what is in the vial matches the label at all?
What is the first thing you would read if you were starting from zero?
Test one thing at a time. It feels slower and it is the only way to learn anything. Not on huperzine A but the pattern is familiar.
Baseline first. Currently on huperzine A myself.
If it needs three other compounds to notice, you have not tested the first one.
How long before you can reasonably say something is or is not doing anything? Currently on huperzine A myself.